Your browser doesn't support javascript.
loading
Mind the gap in kidney care: translating what we know into what we do.
Luyckx, Valerie A; Tuttle, Katherine R; Abdellatif, Dina; Correa-Rotter, Ricardo; Fung, Winston W S; Haris, Agnès; Hsiao, Li-Li; Khalife, Makram; Kumaraswami, Latha A; Loud, Fiona; Raghavan, Vasundhara; Roumeliotis, Stefanos; Sierra, Marianella; Ulasi, Ifeoma; Wang, Bill; Lui, Siu-Fai; Liakopoulos, Vassilios; Balducci, Alessandro.
Afiliação
  • Luyckx VA; University of Zurich, Epidemiology, Biostatistics and Prevention Institute, Department of Public and Global Health, Zurich, Switzerland.
  • Tuttle KR; Harvard Medical School, Brigham and Women's Hospital, Department of Medicine, Renal Division, Boston, Massachusetts, USA.
  • Abdellatif D; University of Cape Town, Department of Paediatrics and Child Health, Cape Town, South Africa.
  • Correa-Rotter R; Providence Inland Northwest Health, Providence Medical Research Center, Spokane, Washington, USA.
  • Fung WWS; University of Washington, Department of Medicine, Nephrology Division, Seattle, Washington, USA.
  • Haris A; Cairo University Hospital, Department of Nephrology, Cairo, Egypt.
  • Hsiao LL; National Medical Science and Nutrition Institute Salvador Zubiran, Department of Nephrology and Mineral Metabolism, Mexico City, Mexico.
  • Khalife M; University of Hong Kong, Prince of Wales Hospital, Department of Medicine and Therapeutics, The Chinese Shatin, Hong Kong, China.
  • Kumaraswami LA; Péterfy Hospital, Nephrology Department, Budapest, Hungary.
  • Loud F; Harvard Medical School, Brigham and Women's Hospital, Department of Medicine, Renal Division, Boston, Massachusetts, USA.
  • Raghavan V; ISN Patient Liaison Advisory Group, Brussel, Belgium.
  • Roumeliotis S; Tamilnad Kidney Research (TANKER) Foundation, Chennai, India.
  • Sierra M; ISN Patient Liaison Advisory Group, Brussel, Belgium.
  • Ulasi I; ISN Patient Liaison Advisory Group, Brussel, Belgium.
  • Wang B; Aristotle University of Thessaloniki, AHEPA University Hospital Medical School, 2nd Department of Nephrology, Thessaloniki, Greece.
  • Lui SF; ISN Patient Liaison Advisory Group, Brussel, Belgium.
  • Liakopoulos V; University of Nigeria, College of Medicine, Department of Medicine, Ituku-Ozalla, Enugu, Nigeria.
  • Balducci A; ISN Patient Liaison Advisory Group, Brussel, Belgium.
J Bras Nefrol ; 46(3): e2024E007, 2024.
Article em En, Pt | MEDLINE | ID: mdl-38991207
ABSTRACT
Historically, it takes an average of 17 years for new treatments to move from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. Now is the time to narrow the gap between what we know and what we do. Clear guidelines exist for the prevention and management of common risk factors for kidney disease, such as hypertension and diabetes, but only a fraction of people with these conditions are diagnosed worldwide, and even fewer are treated to target. Similarly, the vast majority of people living with kidney disease are unaware of their condition, because it is often silent in the early stages. Even among patients who have been diagnosed, many do not receive appropriate treatment for kidney disease. Considering the serious consequences of kidney disease progression, kidney failure, or death, it is imperative that treatments are initiated early and appropriately. Opportunities to diagnose and treat kidney disease early must be maximized beginning at the primary care level. Many systematic barriers exist, ranging from the patient to the clinician to the health systems to societal factors. To preserve and improve kidney health for everyone everywhere, each of these barriers must be acknowledged so that sustainable solutions are developed and implemented without further delay.
Assuntos